These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26149879)

  • 21. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
    Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
    Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract]   [Full Text] [Related]  

  • 24. That's the "GIST" of it: use of adjuvant imatinib after resection of a primary GI stromal tumor.
    Tap WD; Schwartz GK
    J Clin Oncol; 2014 May; 32(15):1543-6. PubMed ID: 24638004
    [No Abstract]   [Full Text] [Related]  

  • 25. Familial and multiple gastrointestinal stromal tumors with fair response to a half-dose of imatinib.
    Bamba S; Hirota S; Inatomi O; Ban H; Nishimura T; Shioya M; Imaeda H; Nishida A; Sasaki M; Murata S; Andoh A
    Intern Med; 2015; 54(7):759-64. PubMed ID: 25832938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
    Judson IR
    J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
    [No Abstract]   [Full Text] [Related]  

  • 27. [A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
    Takeda Y; Nakahira S; Katsura Y; Ohmura Y; Kusama H; Kuroda Y; Goto T; Hashimoto T; Kimura K; Matsushita K; Sato Y; Morimoto Y; Ishida T; Nitta K; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Taniguchi H; Egawa C; Ohzono K; Nakatsuka S; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1545-7. PubMed ID: 25731247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of small intestinal GIST maintained as a long stable disease by imatinib mesylate 400 mg/day, alternate-day administration for 2 weeks followed by a 2 week interval].
    Nakamura T; Shiraishi S; Kitamura N; Taniguchi M; Okauchi H; Shimomatsuya T; Maruhashi K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1695-8. PubMed ID: 21996970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which is the best surgical approach for anorectal gastrointestinal stromal tumors in the post-imatinib era?
    Pucciarelli S; Maretto I
    Tech Coloproctol; 2013 Oct; 17(5):477-8. PubMed ID: 23624793
    [No Abstract]   [Full Text] [Related]  

  • 30. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
    McAuliffe JC; Hunt KK; Lazar AJ; Choi H; Qiao W; Thall P; Pollock RE; Benjamin RS; Trent JC
    Ann Surg Oncol; 2009 Apr; 16(4):910-9. PubMed ID: 18953611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimized dose of imatinib for treatment of gastrointestinal stromal tumors: a meta-analysis.
    Liu SL; Chen G; Zhao YP; Wu WM; Zhang TP
    J Dig Dis; 2013 Jan; 14(1):16-21. PubMed ID: 23121684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
    Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
    Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
    Maurel J; Martins AS; Poveda A; López-Guerrero JA; Cubedo R; Casado A; Martínez-Trufero J; Ramón Ayuso J; Lopez-Pousa A; Garcia-Albeniz X; Garcia del Muro X; de Alava E
    Cancer; 2010 Aug; 116(15):3692-701. PubMed ID: 20564079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
    Eisenberg BL; Harris J; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M
    J Surg Oncol; 2009 Jan; 99(1):42-7. PubMed ID: 18942073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
    Walker EJ; Simko JP; Ko AH
    Anticancer Res; 2014 Jul; 34(7):3629-34. PubMed ID: 24982379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [GIST].
    Doi T
    Gan To Kagaku Ryoho; 2008 May; 35(5):737-9. PubMed ID: 18487909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety evaluation of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GISTs).
    Yang P; Chen B; Zhou Y; Wu XT
    Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):484-90. PubMed ID: 22889747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.
    Angelini S; Ravegnini G; Fletcher JA; Maffei F; Hrelia P
    Pharmacogenomics; 2013 Jun; 14(8):941-56. PubMed ID: 23746188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
    Yeh CN; Fu CJ; Yen TC; Chiang KC; Jan YY; Chen MF
    J Clin Oncol; 2013 Jun; 31(16):e248-50. PubMed ID: 23569321
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.